Exelixis Receivables 2010-2024 | EXEL

Exelixis receivables for the quarter ending June 30, 2024 were $0.397B, a 70.34% increase year-over-year.

  • Exelixis receivables for 2023 were $0.237B, a 10.53% increase from 2022.
  • Exelixis receivables for 2022 were $0.215B, a 24.01% decline from 2021.
  • Exelixis receivables for 2021 were $0.283B, a 75.7% increase from 2020.

Exelixis Receivables 2010-2024 | EXEL

  • Exelixis receivables for 2023 were $0.237B, a 10.53% increase from 2022.
  • Exelixis receivables for 2022 were $0.215B, a 24.01% decline from 2021.
  • Exelixis receivables for 2021 were $0.283B, a 75.7% increase from 2020.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$178.8B
Regeneron Pharmaceuticals (REGN)$126.4B
Vertex Pharmaceuticals (VRTX)$124.2B
Gilead Sciences (GILD)$103.4B
Bristol Myers Squibb (BMY)$100.3B
CSL (CSLLY)$97.4B
GSK (GSK)$88.2B
Alnylam Pharmaceuticals (ALNY)$35.2B
Argenex SE (ARGX)$31.2B
BioNTech SE (BNTX)$29.7B
Biogen (BIIB)$28.9B
Moderna (MRNA)$27.7B
Illumina (ILMN)$20.7B
BeiGene (BGNE)$19.2B
Genmab (GMAB)$17.5B
BioMarin Pharmaceutical (BMRN)$13.4B
Vaxcyte (PCVX)$13B
Incyte (INCY)$12.8B
Insmed (INSM)$12.6B
Exact Sciences (EXAS)$12.6B
Sarepta Therapeutics (SRPT)$12B
Bio-Techne Corp (TECH)$11.9B
QIAGEN (QGEN)$10.4B
Legend Biotech (LEGN)$9.3B
Bio-Rad Laboratories (BIO.B)$9.1B
Roivant Sciences (ROIV)$8.9B
Ascendis Pharma (ASND)$8.5B
Intra-Cellular Therapies (ITCI)$7.9B
Halozyme Therapeutics (HALO)$7.8B
Repligen (RGEN)$7.6B